Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Pro Medicus Limited ( (AU:PME) ).
Pro Medicus Limited has announced a financing agreement with 4DMedical to support the development and commercialization of 4DMedical’s lung function imaging and analysis software. This strategic move is expected to enhance Pro Medicus’s position in the health imaging industry and potentially expand its market reach, benefiting stakeholders through improved product offerings.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is a leading company in the health imaging industry, offering advanced imaging solutions and services. The company focuses on developing and commercializing innovative imaging software products, catering to the healthcare sector.
Average Trading Volume: 188,312
Technical Sentiment Signal: Buy
Current Market Cap: A$33.76B
Learn more about PME stock on TipRanks’ Stock Analysis page.